Magnetically-activated lipid nanocarriers in biomedical applications: A review of current status and perspective
Research output: Contribution to journal › Review › Research › peer-review
Documents
- Fulltext
Final published version, 3.62 MB, PDF document
Magnetically-activated lipid nanocarriers have become a research hotspot in the field of biomedicine. Liposomes and other lipid-based carriers possess good biocompatibility as well as the ability to carrying therapeutic cargo with a range of physicochemical properties. Previous studies have demonstrated that magnetic materials have potential wide applications in clinical diagnosis and therapy, such as in MRI as contrast agents and in hyperthermic obliteration of cancer tissues. More recently magneto-thermal activation of lipid carriers to stimulate drug release has extended the range of further therapeutic benefits. Here, an overview of the current development of magnetically-activated lipid nanocarriers in the field of biomedicine is provided, including the methods of fabrication of the nanocarriers and their in vitro and in vivo performance. A discussion of the current barriers to translation of these materials as medicines is provided in the context of clinical and regulatory complexities of using magnetically responsive materials in therapeutic applications. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology-Inspired Nanomaterials > Lipid-Based Structures Implantable Materials and Surgical Technologies > Nanomaterials and Implants.
Original language | English |
---|---|
Article number | e1863 |
Journal | Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology |
Volume | 15 |
Issue number | 3 |
Number of pages | 22 |
ISSN | 1939-5116 |
DOIs | |
Publication status | Published - 2023 |
Bibliographical note
Funding Information:
Australian Research Council, Grant/Award Number: CE140100036; Novo Nordisk Fonden, Grant/Award Number: NNF Laureate 2020 Funding information
Funding Information:
Xiaohan Sun and Angel Tan received support from the Australian Research Council Centre of Excellence in Bio‐Nano Science and Technology (CE140100036). Ben Boyd is supported by a Novo Nordisk Laureate Research Fellowship (2020).
ID: 328692371